These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 27196492)

  • 61. [Preoperative chemotherapy in the surgical treatment of colorectal liver metastases].
    Dede K; Láng I; Pörneczi B; Mester G; Fekete A; Kőszegi G; Mersich T; Besznyák I; Bursics A
    Magy Seb; 2013 Dec; 66(6):325-30. PubMed ID: 24333977
    [TBL] [Abstract][Full Text] [Related]  

  • 62. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306.
    Stintzing S; Fischer von Weikersthal L; Decker T; Vehling-Kaiser U; Jäger E; Heintges T; Stoll C; Giessen C; Modest DP; Neumann J; Jung A; Kirchner T; Scheithauer W; Heinemann V
    Ann Oncol; 2012 Jul; 23(7):1693-9. PubMed ID: 22219013
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Perioperative complications after neoadjuvant chemotherapy with and without bevacizumab for colorectal liver metastases.
    Lubezky N; Winograd E; Papoulas M; Lahat G; Shacham-Shmueli E; Geva R; Nakache R; Klausner J; Ben-Haim M
    J Gastrointest Surg; 2013 Mar; 17(3):527-32. PubMed ID: 23299220
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Early tumour response as a survival predictor in previously- treated patients receiving triplet hepatic artery infusion and intravenous cetuximab for unresectable liver metastases from wild-type KRAS colorectal cancer.
    Bouchahda M; Boige V; Smith D; Karaboué A; Ducreux M; Hebbar M; Lepère C; Focan C; Guimbaud R; Innominato P; Awad S; Carvalho C; Tumolo S; Truant S; De Baere T; Castaing D; Rougier P; Morère JF; Taieb J; Adam R; Lévi F;
    Eur J Cancer; 2016 Nov; 68():163-172. PubMed ID: 27768923
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Chemotherapy rechallenge after regorafenib treatment in metastatic colorectal cancer: still hope after the last hope?
    Bertocchi P; Aroldi F; Prochilo T; Meriggi F; Beretta GD; Zaniboni A
    J Chemother; 2017 Apr; 29(2):102-105. PubMed ID: 28032528
    [TBL] [Abstract][Full Text] [Related]  

  • 66. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
    Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J
    Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Circulating Tumor Cell Enumeration in a Phase II Trial of a Four-Drug Regimen in Advanced Colorectal Cancer.
    Krebs MG; Renehan AG; Backen A; Gollins S; Chau I; Hasan J; Valle JW; Morris K; Beech J; Ashcroft L; Saunders MP; Dive C
    Clin Colorectal Cancer; 2015 Jun; 14(2):115-22.e1-2. PubMed ID: 25680623
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Impact of early tumor shrinkage on clinical outcome in wild-type-KRAS colorectal liver metastases treated with cetuximab.
    Ye LC; Wei Y; Zhu DX; Chen T; Xu J
    J Gastroenterol Hepatol; 2015 Apr; 30(4):674-9. PubMed ID: 25387601
    [TBL] [Abstract][Full Text] [Related]  

  • 69. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
    Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR
    Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Bevacizumab plus chemotherapy in metastatic colorectal cancer patients treated in clinical practice.
    Rossi L; Veltri E; Zullo A; Zoratto F; Colonna M; Di Seri M; Longo F; Mottolese M; Giannarelli D; Ruco L; Romiti A; Barucca V; Adua D; Tomao S
    Future Oncol; 2012 Sep; 8(9):1193-7. PubMed ID: 23030493
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Hepatic arterial infusion of oxaliplatin plus systemic chemotherapy and targeted therapy for unresectable colorectal liver metastases.
    Boilève A; De Cuyper A; Larive A; Mahjoubi L; Najdawi M; Tazdait M; Gelli M; Tselikas L; Smolenschi C; Malka D; Pignon JP; Ducreux M; Boige V
    Eur J Cancer; 2020 Oct; 138():89-98. PubMed ID: 32871526
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [A Case of a Patient with Rectum Cancer with Multiple Metastases, Who Was Able to Undergo Conversion Therapy Using Alternating mFOLFOX6 and FOLFIRI Regimens in Combination with Alternating Cetuximab and Bevacizumab].
    O'hara H; Yamamoto H
    Gan To Kagaku Ryoho; 2018 Nov; 45(11):1669-1672. PubMed ID: 30449861
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Surgical treatment options following chemotherapy plus cetuximab or bevacizumab in metastatic colorectal cancer-central evaluation of FIRE-3.
    Modest DP; Denecke T; Pratschke J; Ricard I; Lang H; Bemelmans M; Becker T; Rentsch M; Seehofer D; Bruns CJ; Gebauer B; Modest HI; Held S; Folprecht G; Heinemann V; Neumann UP
    Eur J Cancer; 2018 Jan; 88():77-86. PubMed ID: 29195117
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Prognostic impact of additive chemotherapy after curative resection of metachronous colorectal liver metastasis: a single-centre retrospective study.
    Kelm M; Schollbach J; Anger F; Wiegering A; Klein I; Germer CT; Schlegel N; Kunzmann V; Löb S
    BMC Cancer; 2021 May; 21(1):490. PubMed ID: 33941104
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Sogabe S; Komatsu Y; Yuki S; Kusumi T; Hatanaka K; Nakamura M; Kato T; Miyagishima T; Hosokawa A; Iwanaga I; Sakata Y; Asaka M
    Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery.
    Giacchetti S; Itzhaki M; Gruia G; Adam R; Zidani R; Kunstlinger F; Brienza S; Alafaci E; Bertheault-Cvitkovic F; Jasmin C; Reynes M; Bismuth H; Misset JL; Lévi F
    Ann Oncol; 1999 Jun; 10(6):663-9. PubMed ID: 10442188
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
    Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
    Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
    [TBL] [Abstract][Full Text] [Related]  

  • 78. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
    Cremolini C; Loupakis F; Masi G; Lonardi S; Granetto C; Mancini ML; Chiara S; Moretto R; Rossini D; Vitello S; Allegrini G; Tonini G; Bergamo F; Tomasello G; Ronzoni M; Buonadonna A; Bustreo S; Barbara C; Boni L; Falcone A
    Ann Oncol; 2016 May; 27(5):843-9. PubMed ID: 26861604
    [TBL] [Abstract][Full Text] [Related]  

  • 79. FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
    Kaczirek K; Ciuleanu TE; Vrbanec D; Marton E; Messinger D; Liegl-Atzwanger B; Wrba F; Knittelfelder R; Lindner E; Zielinski CC; Streubel B; Brodowicz T
    Clin Colorectal Cancer; 2015 Jun; 14(2):91-8. PubMed ID: 25666295
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Multiagent chemotherapy for isolated colorectal liver metastases: a single-centered retrospective study.
    Reddy SK; Broadwater G; Niedzwiecki D; Barbas AS; Hurwitz HI; Bendell JC; Morse MA; Clary BM
    J Gastrointest Surg; 2009 Jan; 13(1):74-84. PubMed ID: 18685900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.